Dapagliflozin in Patients with Chronic Kidney Disease
University Medical Center Groningen · University of Groningen · +12 more institutions
Abstract
Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.
of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.
Citation impact
- FWCI
- 365.79
- Percentile
- 100%
- References
- 20
Authors
14- HJHiddo J.L. HeerspinkCorresponding
University Medical Center Groningen, University of Groningen
- BVBergur V. Stefánsson
University Medical Center Groningen, AstraZeneca (Sweden)
- RCRicardo Correa‐Rotter
University Medical Center Groningen, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- GMGlenn M. Chertow
University Medical Center Groningen, Stanford University
- TGTom Greene
University Medical Center Groningen, University of Utah
Topics & keywords
- Dapagliflozin
- Kidney disease
- Medicine
- Intensive care medicine
- Internal medicine
- Diabetes mellitus
- Endocrinology
- Type 2 diabetes
- Good health and well-being